Targeted inhibition of SHCBP1‐PLK1 may inhibit the proliferation and metastasis of prostate cancer cells and enhance the chemotherapeutic efficacy of docetaxel in PCa cells. This evidence concerns the gene PLK1 and posterior cortical atrophy.